Nasal Congestion

3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

J&
Johnson & JohnsonNEW BRUNSWICK, NJ
2 programs
1
1
Diphenhydramine 50 mgPhase 41 trial
Diphenhydramine hydrochloridePhase 11 trial
Active Trials
NCT00662337Completed36Est. Nov 2006
NCT00648973Completed1,021Est. May 2007
GSK
GSKLONDON, United Kingdom
1 program
1
Carbon DioxidePhase 21 trial
Active Trials
NCT02113449Completed147Est. Feb 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Johnson & JohnsonDiphenhydramine 50 mg
GSKCarbon Dioxide
Johnson & JohnsonDiphenhydramine hydrochloride

Clinical Trials (3)

Total enrollment: 1,204 patients across 3 trials

NCT00648973Johnson & JohnsonDiphenhydramine 50 mg

To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses

Start: Nov 2006Est. completion: May 20071,021 patients
Phase 4Completed
NCT02113449GSKCarbon Dioxide

Market Potential of Carbon Dioxide Nasal Spray

Start: Nov 2013Est. completion: Feb 2014147 patients
Phase 2Completed
NCT00662337Johnson & JohnsonDiphenhydramine hydrochloride

Bioequivalence Between Two Oral Formulations of Diphenhydramine Hydrochloride

Start: Oct 2006Est. completion: Nov 200636 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space